Personen

Prof. Dr. med. Peter Schirmacher

Ärztlicher Direktor (Allgemeine Pathologie und Pathologische Anatomie)
Geschäftsführender Direktor (Pathologisches Institut)


06221 56-4160

Ärztlicher / Beruflicher Werdegang

seit 2004

Professor of Pathology (C4) and Director, Institute of Pathology, Heidelberg

1998 – 2004

Professor of Pathology (C3), Deputy Director, Institute of Pathology, Cologne

1996

Board Certification Molecular Pathology

1995

Board Certification Pathology

1991 – 1998

Research Associate, Institute of Pathology, University of Mainz

1989 – 1991

Postdoctoral Research Fellowship (DFG); Liver Research Center, Albert Einstein College of Medicine, New York

1987 – 1989

Research Associate, Institute of Pathology, University of Mainz

Wissenschaftlicher Werdegang

1996

Habilitation (Pathology), University of Mainz

1989 – 1991

PhD-Study (Molecular Biology), Liver Research Center, Albert Einstein College of Medicine, New York

1987

MD-Thesis, Institute of Physiology, University of Mainz

1981 – 1987

Study of Medicine, University of Mainz

Auszeichnungen

seit 2012

Member of the Leopoldina, German National Academy of Sciences

1997

Boehringer Ingelheim Award

1987

Johannes Gutenberg Award

Mitgliedschaften

seit 2015

Since 2015 Board member European Society of Pathology (ESP)

seit 2015

Board member National Center of Tumor Diseases (NCT)

seit 2014

Board Member German Telematics Platform (TMF

seit 2013

Board Member International Liver Cancer Association (ILCA)

seit 2011

Board Member German Liver Foundation

2008 – 2016

Member and Speaker (2008-2012) of Section 2 (Cancer and Stem Cell Research), German Research Foundation (DFG)

2007 – 2009

Board Member German Association for Study of the Liver (President 2008-2009)

seit 2007

Board Member German Association of Pathology (DGP)

Ämter und Funktionen

seit 2013

Chairman German Society of Pathology

2012 – 2013

President German Society of Pathology

2011 – 2012

President International Laennec Society of Liver Pathology

seit 2011

Founder and Coordinator of the centralized BiomaterialBank Heidelberg BMBH

seit 2011

Principle Investigator and Coordinator of Biobanking Platforms, GermanConsortium for Translational Cancer Research (DKTK) and German Center for Infectious Diseases Research (DZIF)

2010 – 2014

Coordinator of the SFB/TR77 “Liver Cancer” (DFG)

seit 2006

Co-Founder and Speaker of the Advisory Board 'Tissue Imaging and Analysis Center’ (TIGA), Heidelberg

seit 2005

Founder and Speaker ‘Tissue Bank of the National Center of Tumor Diseases

seit 2005

Founder and Speaker ‘Working Group Tissue Banks of the German Cancer Centers’

2004 – 2010

Managing board Tumorzentrum Heidelberg/Mannheim

2001 – 2004

Managing board ‘Center for Molecular Medicine Cologne’ (CMMC)

1996 – 1998

Managing board DFG-SFB 519

Selected Publications

1. Mogler C, König C, Wieland M, Runge A, Besemfelder E, Komljenovic D, Longerich T, Schirmacher P, Augustin HG. (2017) Hepatic stellate cells limit hepatocellular carcinoma progression through the orphan receptor endosialin. EMBO Mol Med. 9(6):741-749

2. Gdynia G, Sauer SW, Kopitz J, Fuchs D, Duglova K, Ruppert T, Miller M, Pahl J, Cerwenka A, Enders M, Mairbäurl H, Kamiński MM, Penzel R, Zhang C, Fuller JC, Wade RC, Benner A, Chang-Claude J, Brenner H, Hoffmeister M, Zentgraf H, Schirmacher P, Roth W. (2016) The HMGB1 protein induces a metabolic type of tumour cell death by blocking aerobic respiration. Nat Commun 7:10764. (Publication received the Novartis Award 2016 and the Landesforschungspreis Baden-Württemberg 2016)

3. Ploeger C, Waldburger N, Fraas A, Goeppert B, Pusch S, Breuhahn K, Wang XW, Schirmacher P, Roessler S (2016) Chromosome 8p tumor suppressor genes SH2D4A and SORBS3 cooperate to inhibit interleukin-6 signaling in hepatocellular carcinoma. Hepatology 64(3):828-42.

4. Samarin J, Laketa V, Malz M, Roessler S, Stein I, Horwitz E, Singer S, Dimou E, Cigliano A, Bissinger M, Falk CS, Chen X, Dooley S, Pikarsky E, Calvisi DF, Schultz C, Schirmacher P, Breuhahn K. (2016) PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells. Hepatology 63(3):813-26.

5. Rudalska R, Dauch D, Longerich T, McJunkin K, Wuestefeld T, Kang TW, Hohmeyer A, Pesic M, Leibold J, von Thun A, Schirmacher P, Zuber J, Weiss KH, Powers S, Malek NP, Eilers M, Sipos B, Lowe SW, Geffers R, Laufer S, Zender L (2014) In vivo RNAi screening identifies mechanisms of Sorafenib resistance in liver cancer. Nat Med 20(10):1138-46.

6. Pellegrino R, Calvisi DF, Neumann O, Kolluru V, Wesely J, Chen X, Wang C, Wuestefeld T, Ladu S, Elgohary N, Bermejo JL, Radlwimmer B, Zörnig M, Zender L, Dombrowski F, Evert M, Schirmacher P, Longerich T. (2014) EEF1A2 inactivates p53 by way of PI3K/AKT/mTORdependent stabilization of MDM4 in hepatocellular carcinoma. Hepatology 59(5):1886-99.

7. Wuestefeld T, Pesic M, Rudalska R, Dauch D, Longerich T, Kang TW, Yevsa T, Heinzmann F, Hoenicke L, Hohmeyer A, Potapova A, Rittelmeier I, Jarek M, Geffers R, Scharfe M, Klawonn F, Schirmacher P, Malek NP, Ott M, Nordheim A, Vogel A, Manns MP, Zender L (2013) A Direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration. Cell 153(2):389-401.

8. Tschaharganeh DF, Chen X, Latzko P, Malz M, Gaida MM, Felix K, Ladu S, Singer S, Pinna F, Gretz N, Sticht C, Tomasi ML, Delogu S, Evert M, Fan B, Ribback S, Jiang L, Brozzetti S, Bergmann F, Dombrowski F, Schirmacher P, Calvisi DF, Breuhahn K (2013) Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology 144(7):1530-1542.e12.

9. Singer S, Zhao R, Barsotti AM, Ouwehand A, Fazollahi M, Coutavas E, Breuhahn K, Neumann O, Longerich T, Pusterla T, Powers MA, Giles KM, Leedman PJ, Hess J, Grunwald D, Bussemaker HJ, Singer RH, Schirmacher P, Prives C (2012) Nuclear pore component Nup98 is a potential tumor suppressor and regulates posttranscriptional expression of select p53 target genes. Mol Cell 48(5):799-810.

10.Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, Hohmeyer A, Gereke M, Rudalska R, Potapova A, Iken M, Vucur M, Weiss S, Heikenwalder M, Khan S, Gil J, Bruder D, Manns M, Schirmacher P, Tacke F, Ott M, Luedde T, Longerich T, Kubicka S, Zender L (2011) Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 479(7374):547-51.

Fields of Interest

Molecular and morphological digestive tract carcinogenesis (especially liver and pancreas); Tumorigenicrole of growth factor mediated signaling processes; Chronic liver diseases and their role in hepat-carcinogenesis; molecular pathological diagnostics; Biobanking; VirtualMicroscopy

Editorial Boards

Journal  of  Hepatology  (Associate  Editor),  Hepatology,  Virchows Archive,LiverCancer, Pathology Research and Practice, Pathologe